A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP)Analyse prospective des évènements vasculaires thrombotiques au cours de l'étude collaborative européene sur l'aspirine à faible dose dans la polyglobulie
References (10)
Polycythemia vera: myths, mechanisms, and management
Blood
(2002)- et al.
The diagnosis and management of polycythemia vera in the era since the Policytemia Vera Study Group: a survey of American Society of Hematology members’ practice 4 patterns
Blood
(2002) - et al.
Indications for cytoreductive therapy in polycythemia vera and essential thrombocythemia
Hematology
(2004) - et al.
Interferon α in the treatment of polycythemia vera
Ann Hematol
(2000) Anagrelide, a therapy for thrombocythemic states: experience in 577 patients
Am J Med
(1992)
Cited by (60)
Evaluation of different diagnostic tools for detection of acquired von Willebrand syndrome in patients with polycythemia vera or essential thrombocythemia
2022, Thrombosis ResearchCitation Excerpt :Myeloproliferative neoplasms (MPNs) are clonal hematological malignancies, including, among other entities, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) [1]. Patients with MPNs are at increased risk of thromboembolic complications such as splanchnic vein thromboses [2–6], but also at a higher risk of bleeding [6]. The increased bleeding risk is mostly due to intake of antithrombotic drugs for the prevention or treatment of thromboembolic complications, or due to esophageal or gastric varices resulting from splanchnic vein thrombosis [6].
Polycythaemia Vera and Coronary Artery Bypass Graft Surgery: A Systematic Review of the Literature
2022, Heart Lung and CirculationCitation Excerpt :Therefore, anticoagulation and antiplatelet agents have established roles pre and postoperatively [38]. In the European Collaboration of Low-dose Aspirin in Polycythaemia Vera (ECLAP) study, 100 mg daily aspirin was shown to significantly improve clinical outcomes in PV patients, such as mortality, stroke and major venous thromboembolism [39]. Indeed, aspirin was used in all cases reporting postoperative management.
Does Race Play a Role in Complications and Outcomes of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms?
2022, Hematology/ Oncology and Stem Cell TherapyCitation Excerpt :Philadelphia chromosome-negative myeloproliferative neoplasms (MPN)—essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF)—are a group of hematologic malignancies characterized by an overproduction of differentiated hematopoietic cells [1–3]. Previous studies have established the association of MPN with both thrombotic and hemorrhagic complications [4–11]. These vascular complications are associated with an increase in morbidity and mortality [4–7].
Thrombosis in myeloproliferative neoplasms: A clinical and pathophysiological perspective
2021, Thrombosis UpdateCitation Excerpt :Prognosis in MPN varies depending on subtype and individual risk stratification, however thrombosis has been identified to have an independent adverse effect on survival in both PV and ET [22,23]. A prospective analysis of thrombotic events in the European Collaboration on Low-dose Aspirin study (ECLAP) found that cardiovascular events accounted for 45% of all-cause mortality in PV at 2.7 years follow up [24,25]. Risk of thrombosis appears highest at the time of initial diagnosis.
Venous thromboembolism after lower extremity orthopedic surgery: A population-based nationwide cohort study
2021, Research and Practice in Thrombosis and Haemostasis